Update on sarcoidosis;Actualités sur la sarcoïdose

Revue de Pneumologie Clinique

Volumn 61, Issue 3, 2005, Pages 203-210

  Tazi, Abdellatif ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Genetics; HLA system; Pathogenics; Sarcoidosis; Therapeutics

Indexed keywords

TUMOR NECROSIS FACTOR ANTIBODY;

DISEASE COURSE; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HEREDITY; HLA SYSTEM; HUMAN; IMMUNE SYSTEM; PATHOGENESIS; REVIEW; RISK FACTOR; SARCOIDOSIS;

EID: 23144452276     PISSN: 07618417     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0761-8417(05)84813-8     Document Type: Review

References (64)

1. Baughman RP, Lower EE, Du Bois RM. Sarcoidosis. Lancet 2003;361:1111-8.
2. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160:736-55.
3. Tazi A, Hance AJ. Les lymphocytes T dans la sarcoïdose. Presse Med 1999;28:1723-8.
4. Agostini C, Meneghin A, Semenzato G. T-lymphocytes and cytokines in sarcoidosis. Curr Opin Pulm Med 2002;8:435-40.
5. Perez RL, Rivera-Marrero CA, Roman J. Pulmonary granulomatous inflammation: from sarcoidosis to tuberculosis. Semin Respir Infect 2003;78:23-32.
6. Gibejova A, Mrazek F, Subrtova D, Sekerova V, Szotkowska J, Kolek V, et al. Expression of macrophage inflammatory protein-3 beta/CCL19 in pulmonary sarcoidosis. Am J Respir Crit Care Med 2003;167:1695-703.
7. Ota M, Amakawa R, Uehira K, Ito T, Yagi Y, Oshiro A, et al. Involvement of dendritic cells in sarcoidosis. Thorax 2004;59:408-13.
8. Bergeron A, Bonay M, Kambouchner M, Lecossier D, Riquet M, Soler P, et al. Cytokine patterns in tuberculous and sarcoid granulomas: correlations with histopathologic features of the granulomatous response. J Immunol 1997;759:3034-43.
9. Katchar K, Eklund A, Grunewald J. Expression of Th1 markers by lung accumulated T cells in pulmonary sarcoidosis. J Intern Med 2003;254:564-71.
10. Tahan V, Ozseker F, Guneylioglu D, Baran A, Ozaras R, Mert A, et al Sarcoidosis after use of interferon for chronic hepatitis C: report of a case and review of the literature. Dig Dis Sci 2003;48:169-73.
11. Moller DR, Chen ES. What causes sarcoidosis? Curr Opin Pulm Med 2002;8:429-34.
12. Morris DG, Jasmer RM, Huang L, Gotway MB, Nishimura S, King TE Jr. Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence. Chest 2003;124:929-35.
13. Foulon G, Wislez M, Naccache JM, Blanc FX, Rabbat A, Israel-Biet D, et al. Sarcoidosis in HIV-infected patients in the era of highly active antiretroviral therapy. Clin Infect Dis 2004;58:418-25.
14. Lammas DA, De Heer E, Edgar JD, Novelli V, Ben-Smith A, Baretto R, et al. Heterogeneity in the granulomatous response to mycobacterial infection in patients with defined genetic mutations in the interleukin 12-dependent interferon-gamma production pathway. Int J Exp Pathol 2002;83:1-20.
15. Shigehara K, Shijubo N, Ohmichi M, Takahashi R, Kon S, Okamura H, et al. IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. J Immunol 2001;166:642-9.
16. Larousserie F, Pflanz S, Coulomb-L'Hermine A, Brousse N, Kastelein R, Devergne O. Expression of IL-27 in human Th1-associated granulomatous diseases. J Pathol 2004;202:164-71.
17. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
18. Planck A, Katchar K, Eklund A, Gripenback S, Grunewald J. T-lymphocyte activity in HLA-DR17 positive patients with active and clinically recovered sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003;20:110-7.
19. Moller DR. Pulmonary fibrosis of sarcoidosis. New approaches, old ideas. Am J Respir Cell Mol Biol 2003;29:S37-41.
20. Du Bois RM, Goh N, McGrath D, Cullinan P. Is there a role for microorganisms in the pathogenesis of sarcoidosis? J Intern Med 2003;253:4-17.
21. Rybicki BA, Iannuzzi MC, Frederick MM, Thompson BW, Rossman MD, Bresnitz EA, et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001;764:2085-91.
22. Luisetti M, Beretta A, Casali L. Genetic aspects in sarcoidosis. Eur Respir J 2000;16:768-80.
23. Schurmann M, Lympany PA, Reichel P, Muller-Myhsok B, Wurm K, Schlaak M, et al. Familial sarcoidosis is linked to the major histocompatibility complex region. Am J Respir Crit Care Med 2000;162:861-4.
24. Moller DR, Chen ES. Genetic basis of remitting sarcoidosis: triumph of the trimolecular complex? Am J Respir Cell Mol Biol 2002;27:391-5.
25. Iannuzzi MC, Maliarik MJ, Poisson LM, Rybicki BA. Sarcoidosis susceptibility and resistance HLA-DQB1 alleles in African Americans. Am J Respir Crit Care Med 2003;167:1225-31.
26. Sharma SK, Balamurugan A, Pandey RM, Saha PK, Mehra NK. Human leukocyte antigen-DR alleles influence the clinical course of pulmonary sarcoidosis in Asian Indians. Am J Respir Cell Mol Biol 2003;29:225-31.
27. Spagnolo P, Renzoni EA, Wells AU, Sato H, Grutters JC, Sestini P, et al. CC chemokine receptor 2 and sarcoidosis: association with Lofgren's syndrome. Am J Respir Crit Care Med 2003;168:1162-6.
28. Wysoczanska B, Bogunia-Kubik K, Suchnicki K, Mlynarczewska A, Lange A. Combined association between IFN-gamma 3,3 homozygosity and DRB1*03 in Lofgren's syndrome patients. Immunol Lett 2004;97:127-31.
29. Grunewald J, Eklund A, Olerup O. Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients. Am J Respir Crit Care Med 2004;169:696-102.
30. Rybicki BA, Iannuzzi MC. Sarcoidosis and human leukocyte antigen class I and II genes: it takes two to tango? Am J Respir Crit Care Med 2004;169:665-6.
31. Schurmann M, Valentonyte R, Hampe J, Muller-Quernheim J, Schwinger E, Schreiber S. CARD15 gene mutations in sarcoidosis. Eur Respir J 2003;22:748-54.
32. Martin TM, Doyle TM, Smith JR, Dinulescu D, Rust K, Rosenbaum JT. Uveitis in patients with sarcoidosis is not associated with mutations in NOD2 (CARD15). Am J Ophthalmol 2003;136:933-5.
33. Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med 2004;170:1324-30.
34. Hance AJ. The role of mycobacteria in the pathogenesis of sarcoidosis. Semin Respir Infect 1998;13:197-205.
35. Nishiwaki T, Yoneyama H, Eishi Y, Matsuo N, Tatsumi K, Kimura H, et al. Indigenous pulmonary Propionibacterium acnes primes the host in the development of sarcoid-like pulmonary granulomatosis in mice. Am J Pathol 2004;165:631-9.
36. Ziegenhagen MW, Muller-Quernheim J. The cytokine network in sarcoidosis and its clinical relevance. J Intern Med 2003;253:18-30.
37. Drent M, De Vries J, Lenters M, Lamers RJ, Rothkranz-Kos S, Wouters EF, et al. Sarcoidosis: assessment of disease severity using HRCT. Eur Radiol 2003;13:2462-71.
38. Grutters JC, Fellrath JM, Mulder L, Janssen R, van den Bosch JM, van Velzen-Blad H. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation. Chest 2003;124:186-95.
39. Ziora D, Kaluska K, Kozielski J. An increase in exhaled nitric oxide is not associated with activity in pulmonary sarcoidosis. Eur Respir J 2004;24:609-14.
40. Kobayashi S, Kaneko Y, Seino K, Yamada Y, Motohashi S, Koike J, et al. Impaired IFN-gamma production of Valpha24 NKT cells in non-remitting sarcoidosis. Int Immunol 2004;16:215-22.
41. Shorr AF, Helman DL, Lettieri CJ, Montilla JL, Bridwell RS. Depreotide scanning in sarcoidosis: a pilot study. Chest 2004;126:1337-43.
42. Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA 2002;287:1301-7.
43. Paramothayan S, Lasserson T, Walters EH. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst Rev 2003:CD003536.
44. Baughman RP, Lower EE. New therapies for sarcoidosis. Clinical Pulmonary Medicine 2004;11:154-60.
45. Johns CJ, Michele TM. The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. Medicine (Baltimore) 1999;78:65-111.
46. Sugisaki K, Yamaguchi T, Nagai S, Ohmiti M, Takenaka S, Morimoto S, et al. Clinical characteristics of 195 Japanese sarcoidosis patients treated with oral corticosteroids. Sarcoidosis Vasc Diffuse Lung Dis 2003;20:222-6.
47. Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999;160:192-7.
48. Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 2001;137:69-73.
49. Muller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999;14:1117-22.
50. Doty JD, Mazur JE, Judson MA. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest 2003;124:2023-6.
51. Chapelon-Abric C, De Zuttere D, Duhaut P, Veyssier P, Wechsler B, Lê Thi Huong Du, et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore) 2004;83:315-34.
52. Ziegenhagen MW, Rothe ME, Zissel G, Muller-Quernheim J. Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:185-90.
53. Rybojad M. Prise en charge des atteintes cutanées sévères de la sarcoïdose. Ann Med Interne (Paris) 2001;152:89-95.
54. Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003;124:177-85.
55. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5.
56. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med 2001;135:27-31.
57. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:70-4.
58. Pettersen JA, Zochodne DW, Bell RB, Martin L, Hill MD. Refractory neurosarcoidosis responding to infliximab. Neurology 2002;59:1660-1.
59. Serio RN. Infliximab treatment of sarcoidosis. Ann Pharmacother 2003;37:577-81.
60. Roberts SD, Wilkes DS, Burgett RA, Knox KS. Refractory sarcoidosis responding to infliximab. Chest 2003;124:2028-31.
61. Carter JD, Valeriano J, Vasey FB, Bognar B. Refractory neurosarcoidosis: a dramatic response to infliximab. Am J Med 2004;117:277-9.
62. Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis 2004;63:318-20.
63. Agostini C. Cytokine and chemokine blockade as immunointervention strategy for the treatment of diffuse lung diseases. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:18-22.
64. Moller DR. Treatment of sarcoidosis: from a basic science point of view. J Intern Med 2003;253:3l-40.